Episode

EASD 2025: Golden Anniversary - 50 years of attending the EASD Annual Meeting

Podcast
Diabetes Insights - Breakthroughs and Innovators
Published
Jun 12, 2026
Duration seconds
646
Processing state
not_requested
Canonical source
https://diabetes-insights.podigee.io/67-easd-2025-golden-anniversary-50-years-of-attending-the-easd-annual-meeting
Audio
https://audio.podigee-cdn.net/2518387-m-073966db71e81e247c42bbe937807638.mp3?source=feed
JSON
/v1/public/podcasts/diabetes-insights-breakthroughs-and-innovators-7109701/episodes/easd-2025-golden-anniversary-50-years-of-attending-the-easd-annual-meeting
Markdown
/podcast/diabetes-insights-breakthroughs-and-innovators-7109701/easd-2025-golden-anniversary-50-years-of-attending-the-easd-annual-meeting.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/diabetes-insights-breakthroughs-and-innovators-7109701/episodes/easd-2025-golden-anniversary-50-years-of-attending-the-easd-annual-meeting/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/diabetes-insights-breakthroughs-and-innovators-7109701/easd-2025-golden-anniversary-50-years-of-attending-the-easd-annual-meeting.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode, Prof. Eberhard Standl marks an extraordinary milestone - 50 years since attending his first EASD Congress. Looking back on a career spanning five decades, he shares how diabetes care has evolved from the challenges of diabetic ketoacidosis in the 1970s to today's advances in continuous glucose monitoring, hybrid closed-loop systems, immunotherapies, and the potential reversal of type 2 diabetes. Prof. Standl discusses the enduring importance of lifestyle interventions, the value of long-term partnerships between clinicians and people living with diabetes, and emerging research linking diabetes, obesity, metabolism, and cancer. He also reflects on the collaborative spirit of the diabetes research community and the exciting possibilities that lie ahead for both type 1 and type 2 diabetes.